Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/14/15Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis
First Clinical Study of an Ecobiotic® Microbiome Therapeutic in a Chronic, Non-infectious Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 14, 2015-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has initiated a Phase 1b clinical trial evaluating SER-287 in mild-to-moderate ulcerative colitis (UC). The program IND has been cleared by the FDA, and clinical investigational sites are now ... 
 Printer Friendly Version
11/10/15Seres Therapeutics Appoints Kurt Graves to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2015-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced the appointment of Kurt Graves to the company’s board of directors. Mr. Graves, the Chairman, President and CEO of Intarcia Therapeutics, is an industry leader who brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies. He has developed and lau... 
 Printer Friendly Version
11/10/15Seres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update
FDA granted Orphan Drug Designation for SER-109 in recurrent C. difficile infection (CDI) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2015-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported financial results and provided a business update for the third quarter ended September 30, 2015. “Over the past few months, we have continued to make significant progress in the microb... 
 Printer Friendly Version
11/04/15Seres Therapeutics to Host Third Quarter 2015 Financial Results Conference Call and Webcast on Nov. 10, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2015-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, announced today that management will host a conference call and live audio webcast on Tuesday, Nov. 10, 2015, at 10 a.m. EST to discuss financial results for the third quarter ended Sept. 30, 2015, and to provide a business update. To access the conference call, please dial 888-834-1266 (domestic) or ... 
 Printer Friendly Version
10/29/15Seres Therapeutics to Participate in November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 29, 2015-- Seres Therapeutics Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, today announced its participation in two upcoming investor conferences in November: Citi 2015 Global Healthcare Conference in New York City on Wednesday, November 4, 2015. Seres’ management will participate in one-to-one and small-group meetings. Credit Suisse 24th An... 
 Printer Friendly Version
09/02/15Seres Therapeutics to Present at 22nd Annual BioCentury NewsMakers Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 2, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, today announced that management will present a company overview at BioCentury’s 22nd Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY. The presentation is scheduled for Thursday, September 10, 2015 at 2:30 p.m. (EDT). Live audio webcast of the pre... 
 Printer Friendly Version
08/21/15Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SER-109, an oral therapeutic currently in a Phase 2 clinical trial for the prevention of recurrent Clostridium difficile infection (CDI) in adults. SER-109 is being investigated as a new therapeutic modality ... 
 Printer Friendly Version
08/06/15Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update
- Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection (CDI) in adults - FDA Breakthrough Therapy Designation received for SER-109 - Successfully completed initial public offering CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2015-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company developing a novel class of biological drugs... 
 Printer Friendly Version
08/05/15Seres Therapeutics to Present at Canaccord Genuity 35th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, today announced that management will present a company overview at the Canaccord Genuity 35th Annual Growth Conference held at the InterContinental Hotel in Boston, Mass. The presentation is scheduled for Thursday, August 13, 2015 at 3:00 p.m. (EDT). Live audio webcast of the presentation will be av... 
 Printer Friendly Version
07/01/15Seres Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 1, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the closing of its initial public offering of 8,545,138 shares of its common stock at an initial public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,114,583 additional shares of common stock. The shares began trading on the NASDAQ Global Select Market under the ticker symbol... 
 Printer Friendly Version
06/25/15Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2015-- Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of com... 
Download PDFPrinter Friendly Version
06/12/15Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, today announced that SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated), its lead product candidate under investigation for the prevention of recurrent Clostridium difficile infection (CDI) in adults, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). Breakthrough therapy designat... 
Download PDFPrinter Friendly Version
06/11/15Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr. Ausiello, the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Chair of Medicine, Emeritus a... 
Download PDFPrinter Friendly Version
05/28/15Seres Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, announced today the enrollment and dosing of the first patient in its Phase 2 clinical study of SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent Clostridium difficile infection (CDI) in adults. The objective of the Phase 2 study is to further assess the efficacy and safety of SER-109, Seres’ leading... 
Download PDFPrinter Friendly Version
01/21/15Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board
CAMBRIDGE, Mass., Jan. 21, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today the addition of Mark Wilcox, M.D., of the University of Leeds, to its Scientific Advisory Board (SAB). "Mark is one of the foremost experts o... 
Download PDFPrinter Friendly Version
01/15/15Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer
CAMBRIDGE, Mass., Jan.15, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, today announced the appointment of Michele (Shelley) Trucksis, Ph.D., M.D., as Executive Vice President and Chief Medical Officer.  In this role, Dr. Trucksis will be responsible for overseeing the clinical development and operat... 
Download PDFPrinter Friendly Version
01/06/15Seres Health Announces $65 Million Investment from Nestle Health Science
CAMBRIDGE, Mass., Jan. 6, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today that it has completed a $65 million Series D preferred stock investment by Nestle Health Science, a wholly-owned subsidiary of Nestle.  Together with its recently announced $48 million Series C preferred stock fin... 
Download PDFPrinter Friendly Version